SG11201705767PA - Agent for preventing and/or treating amyotrophic lateral sclerosis - Google Patents
Agent for preventing and/or treating amyotrophic lateral sclerosisInfo
- Publication number
- SG11201705767PA SG11201705767PA SG11201705767PA SG11201705767PA SG11201705767PA SG 11201705767P A SG11201705767P A SG 11201705767PA SG 11201705767P A SG11201705767P A SG 11201705767PA SG 11201705767P A SG11201705767P A SG 11201705767PA SG 11201705767P A SG11201705767P A SG 11201705767PA
- Authority
- SG
- Singapore
- Prior art keywords
- preventing
- agent
- lateral sclerosis
- amyotrophic lateral
- treating amyotrophic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015004589 | 2015-01-13 | ||
JP2015137909 | 2015-07-09 | ||
PCT/JP2016/050883 WO2016114322A1 (ja) | 2015-01-13 | 2016-01-13 | 筋萎縮性側索硬化症の予防及び/又は治療剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201705767PA true SG11201705767PA (en) | 2017-08-30 |
Family
ID=56405863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201705767PA SG11201705767PA (en) | 2015-01-13 | 2016-01-13 | Agent for preventing and/or treating amyotrophic lateral sclerosis |
Country Status (6)
Country | Link |
---|---|
US (1) | US20180000771A1 (de) |
EP (2) | EP3246046A4 (de) |
JP (1) | JP6852848B2 (de) |
CN (2) | CN113181362B (de) |
SG (1) | SG11201705767PA (de) |
WO (1) | WO2016114322A1 (de) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201714316D0 (en) * | 2017-09-06 | 2017-10-18 | Benevolentai Ltd | Treatement of neurodegenerative diseases |
US20200368267A1 (en) * | 2017-11-24 | 2020-11-26 | Kyoto University | Prophylactic and/or therapeutic agent for amyotrophic lateral sclerosis |
WO2020036934A1 (en) * | 2018-08-13 | 2020-02-20 | The Regents Of The University Of Michigan | Methods for treating amyotrophic lateral sclerosis |
US20220023255A1 (en) * | 2018-12-07 | 2022-01-27 | The Johns Hopkins University | Methods, compositions and kits for treating multiple sclerosis and other disorders |
TW202122082A (zh) | 2019-08-12 | 2021-06-16 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
MX2022001863A (es) | 2019-08-12 | 2022-05-30 | Deciphera Pharmaceuticals Llc | Metodos para tratar los tumores del estroma gastrointestinal. |
US20230322683A1 (en) | 2019-10-18 | 2023-10-12 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
AU2020417282B2 (en) | 2019-12-30 | 2023-08-31 | Deciphera Pharmaceuticals, Llc | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
PL4084778T3 (pl) | 2019-12-30 | 2024-03-04 | Deciphera Pharmaceuticals, Llc | Formulacje amorficznych inhibitorów kinazy i sposoby ich zastosowania |
WO2021193982A1 (ja) * | 2020-03-27 | 2021-09-30 | 国立大学法人京都大学 | 神経細胞変性阻害剤 |
WO2023212411A1 (en) * | 2022-04-29 | 2023-11-02 | Indiana University Research And Technology Corporation | Methods of treating neuropathy using foretinib and compositions thereof |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4133814A (en) | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
FR2688138B1 (fr) | 1992-03-06 | 1995-05-05 | Rhone Poulenc Rorer Sa | Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique. |
US5352708A (en) | 1992-09-21 | 1994-10-04 | Allergan, Inc. | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
BRPI0108394B8 (pt) | 2000-02-15 | 2021-05-25 | Upjohn Co | inibidores de proteína de quinase de 2-indolinona de pirrol substituído, seus sais e composições farmacêuticas compreendendo os mesmos |
SI2311825T1 (sl) | 2000-12-21 | 2016-02-29 | Novartis Ag | Pirimidinamini kot angiogenetski modulatorji |
MXPA03009662A (es) | 2001-04-27 | 2004-12-06 | Kirin Brewery | Derivados de quinolina y derivados de quinazolina que tienen grupos azolilo. |
TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
JP2005531544A (ja) * | 2002-05-06 | 2005-10-20 | ワシントン・ユニバーシティ | Egfr経路の抑制による緑内障およびnos−2発現により媒介される他の状態の治療方法 |
PT1603570E (pt) | 2003-02-26 | 2013-03-26 | Sugen Inc | Compostos de aminoheteroarilo como inibidores da proteína quinase |
JPWO2004091663A1 (ja) * | 2003-04-18 | 2006-07-06 | 協和醗酵工業株式会社 | 神経再生薬 |
CA2543163A1 (en) | 2003-11-06 | 2005-05-26 | Wyeth | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml) |
WO2006042362A1 (en) * | 2004-10-18 | 2006-04-27 | Medvet Science Pty Ltd | Use of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide to inhibit the tyrosine kinase receptor c-fms |
US20090143433A1 (en) * | 2004-12-01 | 2009-06-04 | Curt Hendrix | Cocktail for modulation of alzheimer's disease |
WO2008031835A2 (en) * | 2006-09-13 | 2008-03-20 | Novartis Ag | Method of treating autoimmune diseases using vegf-pathway inhibitors |
GB2458259A (en) * | 2008-02-05 | 2009-09-16 | Univ Aberdeen | Neuroprotective 3-phenylacrylonitrile (3-PAN) derivatives |
US8993615B2 (en) * | 2008-08-08 | 2015-03-31 | The Johns Hopkins University | Compositions and methods for treatment of neurodegenerative disease |
US9265764B2 (en) * | 2009-02-27 | 2016-02-23 | Massachusetts Institute Of Technology | Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders |
AU2010322796A1 (en) * | 2009-11-27 | 2012-07-12 | Proteologics, Ltd. | Quinazolin-4(3A)-one derivatives and methods of use thereof |
US20130115622A1 (en) | 2009-12-14 | 2013-05-09 | Kyoto University | Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis |
EP2611437B1 (de) * | 2010-09-02 | 2017-03-29 | Kyoto University | Pharmazeutische zusammensetzung zur vorbeugung und behandlung von amyotropher lateralsklerose |
US20130274235A1 (en) * | 2010-10-08 | 2013-10-17 | The General Hospital Corporation | Treatment of motor neuron disease |
JP6023082B2 (ja) * | 2011-01-24 | 2016-11-09 | インセプタム リサーチ アンド セラピューティクス,インク. | 精神神経性の疾病を処置するためのプロスタグランジンを含む組成物 |
WO2013108926A1 (en) | 2012-01-17 | 2013-07-25 | Kyoto University | Prophylactic and therapeutic drug for amyotrophic lateral sclerosis and method of screening therefor |
EP2626073A1 (de) * | 2012-02-13 | 2013-08-14 | Harmonic Pharma | Verbindung zur Verwendung zur Prävention bzw. Behandlung einer neurogenerativen Erkrankung oder einer Erkrankung mit Phosphodiesterase (PDE4) -4-Aktivierung |
WO2013166295A1 (en) * | 2012-05-02 | 2013-11-07 | Georgetown University | Treating neural disease with tyrosine kinase inhibitors |
TR201807023T4 (tr) * | 2012-05-15 | 2018-06-21 | Novartis Ag | Abl1, abl2 ve bcr- abl1 aktivitesinin inhibe edilmesi için benzamid türevleri. |
US9539259B2 (en) * | 2012-05-23 | 2017-01-10 | The Johns Hopkins University | Compounds and methods of use thereof for treating neurodegenerative disorders |
US20150152083A1 (en) * | 2012-06-06 | 2015-06-04 | Irm Llc, A Delaware Limited Liability Company | Compounds and Compositions for Modulating EGFR Activity |
EP2977449B1 (de) | 2013-03-21 | 2020-02-26 | Kyoto University | Pluripotente stammzelle zur herbeiführung einer neuronalen differenzierung |
US20160082015A1 (en) * | 2013-04-18 | 2016-03-24 | President And Fellows Of Harvard College | Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders |
JP6138602B2 (ja) | 2013-06-21 | 2017-05-31 | 前田建設工業株式会社 | 孔壁内面形状の計測装置 |
JP2015137909A (ja) | 2014-01-22 | 2015-07-30 | 株式会社島津製作所 | エッチングモニタ装置 |
-
2016
- 2016-01-13 CN CN202110214048.2A patent/CN113181362B/zh active Active
- 2016-01-13 EP EP16737393.5A patent/EP3246046A4/de not_active Withdrawn
- 2016-01-13 US US15/543,171 patent/US20180000771A1/en active Pending
- 2016-01-13 WO PCT/JP2016/050883 patent/WO2016114322A1/ja active Application Filing
- 2016-01-13 JP JP2016569491A patent/JP6852848B2/ja active Active
- 2016-01-13 SG SG11201705767PA patent/SG11201705767PA/en unknown
- 2016-01-13 EP EP20201324.9A patent/EP3789027A1/de active Pending
- 2016-01-13 CN CN201680013824.XA patent/CN107530430A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3246046A4 (de) | 2018-12-05 |
US20180000771A1 (en) | 2018-01-04 |
CN113181362B (zh) | 2023-06-13 |
CN107530430A (zh) | 2018-01-02 |
EP3789027A1 (de) | 2021-03-10 |
WO2016114322A1 (ja) | 2016-07-21 |
CN113181362A (zh) | 2021-07-30 |
JPWO2016114322A1 (ja) | 2017-10-19 |
EP3246046A1 (de) | 2017-11-22 |
JP6852848B2 (ja) | 2021-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL278001B (en) | Preparations and methods for the treatment of amyotrophic lateral sclerosis | |
SG11201705767PA (en) | Agent for preventing and/or treating amyotrophic lateral sclerosis | |
EP3119797A4 (de) | Zusammensetzungen und verfahren zur behandlung von amyotropher lateralsklerose | |
IL257587B (en) | Compounds for treating amyotrophic lateral sclerosis | |
PL3668509T3 (pl) | Sposób leczenia stwardnienia zanikowego bocznego pridopidiną | |
SG11201803669UA (en) | Microorganism-controlling agent and miticidal composition | |
ZA201907975B (en) | Agent for preventing or treating tauopathy | |
ZA201907973B (en) | Agent for preventing or treating brain atrophy | |
IL291266A (en) | Preparations and methods for treating infections | |
PL3129378T3 (pl) | Związki hamujące bromodomenę i zawierająca je kompozycja farmaceutyczna do zapobiegania lub leczenia nowotworu | |
EP3290053A4 (de) | Externes mittel zur behandlung von hyperhidrose | |
IL283833A (en) | Preparations and methods for the treatment and prevention of lateral column sclerosis in the spine | |
IL254619A0 (en) | Biotin for the treatment of lateral column sclerosis in the spine | |
PT3290051T (pt) | Composição farmacêutica para o tratamento e/ou prevenção de cancro | |
IL260331A (en) | Composition and method for treating amyotrophic lateral sclerosis | |
PL3658174T3 (pl) | Laktoferycyna i laktoferampina do leczenia infekcji | |
ZA201802268B (en) | Methods and compositions for preventing or treating cancer | |
HK1249035A1 (zh) | 降低成像後胰腺炎風險的組合物和方法 | |
IL261360A (en) | Compound and method for treating amyotrophic lateral sclerosis | |
IL257407A (en) | Compositions and methods for treating wounds | |
GB2558090B (en) | Prevention and treatment for microbial infections | |
PT3508202T (pt) | Agente terapêutico para a esclerose lateral amiotrófica e composição para o tratamento | |
EP3648768C0 (de) | Imeglimin zur prävention und/oder behandlung von leberzellkarzinomen | |
SG11201804140PA (en) | Acidic-gas treating agent and acidic-gas treating method | |
GB201617590D0 (en) | Methods for the treatment and prevention of ebola |